Emerald Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.58M Buy
1,318
+158
+14% +$161K 0.2% 38
2026
Q1
$1.07M Buy
1,160
+69
+6% +$70K 0.13% 48
2025
Q4
$1.17M Buy
1,091
+6
+0.6% +$5.74K 0.16% 47
2025
Q3
$828K Buy
1,085
+64
+6% +$47.6K 0.11% 55
2025
Q2
$796K Buy
1,021
+386
+61% +$300K 0.1% 55
2025
Q1
$524K Hold
635
0.07% 63
2024
Q4
$490K Hold
635
0.07% 62
2024
Q3
$583K Hold
635
0.08% 58
2024
Q2
$575K Hold
635
0.09% 56
2024
Q1
$494K Hold
635
0.09% 59
2023
Q4
$370K Hold
635
0.07% 65
2023
Q3
$341K Buy
635
+1
+0.2% +$515 0.08% 64
2023
Q2
$297K Buy
634
+1
+0.2% +$419 0.07% 69
2023
Q1
$217K Sell
633
-6
-0.9% -$2.02K 0.06% 76
2022
Q4
$234K Buy
639
+17
+3% +$6.03K 0.06% 66
2022
Q3
$201K Buy
622
+1
+0.2% +$317 0.06% 74
2022
Q2
$201K Buy
+621
New +$186K 0.06% 81

Other funds holding LLY

Emerald Advisors's LLY Position: Q2 2026 in Review

Emerald Advisors increased its Eli Lilly (LLY) stake by 14% in Q2 2026, buying an estimated $161K and bringing the position to 1,318 shares worth $1.58M. The position accounts for 0.2% of the portfolio, ranked #38.

Emerald Advisors first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. 876 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Emerald Advisors held 1,318 shares of Eli Lilly worth $1.58M as of Q2 2026.
  • Emerald Advisors bought 158 Eli Lilly shares in Q2 2026, an estimated $161K.
  • Eli Lilly made up 0.2% of Emerald Advisors's portfolio in Q2 2026, its #38 holding.
  • Emerald Advisors first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
  • 876 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Emerald Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.